Agios begins dosing in Phase I trial of AG-881 in patients with advanced solid tumors with IDH
In preclinical studies, AG-881 was shown to fully penetrate the blood-brain barrier and inhibit IDH1 and IDH2 mutations in cancer models. IDH1 and IDH2 are two metabolic enzymes